Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion.
- Resource Type
- Article
- Source
- Human Cell; Sep2023, Vol. 36 Issue 5, p1716-1728, 13p
- Subject
GRAFT versus host disease HEMATOPOIETIC stem cell transplantation CYTOKINE release syndrome CHIMERIC antigen receptors LYMPHOCYTES - Language
- ISSN
- 09147470